CPRX.NASDAQCatalyst Pharmaceuticals, INC

Form 4: Catalyst Pharmaceuticals Director Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)

📋All filings for Catalyst Pharmaceuticals, INC
🔒Login to Follow

David S Tierney, a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Summary

  • Disposition to the issuer: disposed of 383,314 Common Stock, par value $0.001 per share at $31.50 ($12,074,391) on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 33,500 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 30,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 20,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 15,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 29,524 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 23,248 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 18,115 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 1,414 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 1,894 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 5,468 Restricted Stock Units on July 15, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

David S Tierney — Director

DateTransactionSecuritySharesPriceValueHeld After
2026-07-15Disposition to the issuerCommon Stock, par value $0.001 per share383,314$32$12.1M0
2026-07-15Disposition to the issuerOptions to purchase common stock33,500——0
2026-07-15Disposition to the issuerOptions to purchase common stock30,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock20,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock15,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock29,524——0
2026-07-15Disposition to the issuerOptions to purchase common stock23,248——0
2026-07-15Disposition to the issuerOptions to purchase common stock18,115——0
2026-07-15Disposition to the issuerRestricted Stock Units1,414——0
2026-07-15Disposition to the issuerRestricted Stock Units1,894——0
2026-07-15Disposition to the issuerRestricted Stock Units5,468——0

Key Dates

DateDescription
2026-07-15Disposition to the issuer (383,314 shares)
2026-07-15Disposition to the issuer (33,500 shares)
2026-07-15Disposition to the issuer (30,000 shares)
2026-07-15Disposition to the issuer (20,000 shares)
2026-07-15Disposition to the issuer (15,000 shares)
2026-07-15Disposition to the issuer (29,524 shares)
2026-07-15Disposition to the issuer (23,248 shares)
2026-07-15Disposition to the issuer (18,115 shares)
2026-07-15Disposition to the issuer (1,414 shares)
2026-07-15Disposition to the issuer (1,894 shares)
2026-07-15Disposition to the issuer (5,468 shares)

Keywords

insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, David S Tierney

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.